Table 4.
Sensitivity and specificity of single and combined mutations of hepatitis B virus for the prediction of hepatocellular carcinoma*
| Mutation status | No. of HCC patients | No. of patients without HCC† | Sensitivity, % (95% CI) | Specificity, % (95% CI) |
| PreS‡ | ||||
| Positive | 187 | 219 | 48.2 (43.2 to 53.2) | 80.7 (78.4 to 83.0) |
| Negative | 201 | 915 | ||
| C1653T‡ | ||||
| Positive | 257 | 225 | 40.0 (33.4 to 40.1) | 81.9 (79.8 to 84.0) |
| Negative | 438 | 1018 | ||
| T1753V‡ | ||||
| Positive | 317 | 284 | 39.0 (35.7 to 42.4) | 79.7 (77.6 to 81.8) |
| Negative | 495 | 1113 | ||
| A1762T/G1764A‡ | ||||
| Positive | 1566 | 1861 | 70.6 (68.7 to 72.5) | 60.6 (59.2 to 62.0) |
| Negative | 651 | 2863 | ||
| C1653T + T1753V | ||||
| Positive | 40 | 17 | 20.6 (14.9 to 26.3) | 92.6 (89.2 to 96.0) |
| Negative | 154 | 212 | ||
| A1762T/G1764A + PreS | ||||
| Positive | 24 | 22 | 43.6 (30.5 to 56.7) | 79.2 (71.5 to 87.0) |
| Negative | 31 | 84 | ||
| A1762T/G1764A + C1653T | ||||
| Positive | 66 | 31 | 43.4 (35.5 to 51.3) | 84.2 (79.1 to 89.3) |
| Negative | 86 | 165 | ||
| A1762T/G1764A + T1753V | ||||
| Positive | 106 | 62 | 51.7 (44.9 to 58.5) | 80.4 (76.1 to 84.8) |
| Negative | 99 | 255 | ||
| A1762T/G1764A + C1653T + T1753V | ||||
| Positive | 37 | 12 | 24.3 (17.5 to 31.1) | 93.9 (90.5 to 97.2) |
| Negative | 115 | 184 | ||
*
Data extracted from all included studies. CI = confidence interval; HCC = hepatocellular carcinoma.
†
Includes asymptomatic hepatitis B surface antigen carriers, and patients with chronic hepatitis B or liver cirrhosis, and unclassified hepatitis B virus–infected participants without HCC.
‡
Includes the indicated mutation alone and in combination with other mutations.